Last reviewed · How we verify
NVN1000
At a glance
| Generic name | NVN1000 |
|---|---|
| Also known as | Nitric Oxide 0.3% |
| Sponsor | Novan, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (PHASE3)
- P3 Study in Acne Comparing Once Daily SB204 and Vehicle (PHASE3)
- P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (PHASE2)
- P3 Long Term Safety Study of Once Daily SB204 in Acne (PHASE3)
- A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum (PHASE2)
- Topical NVN1000 for the Treatment of External Genital and Perianal Warts (PHASE2)
- Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers (PHASE1)
- A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVN1000 CI brief — competitive landscape report
- NVN1000 updates RSS · CI watch RSS
- Novan, Inc. portfolio CI